BackgroundInfluenza virus is a single-stranded RNA virus, segmented, 70nm in diameter and enveloped. Strains are described by geographic origin, strain number, year of isolation and hemagglutination (H) and neuraminidase (N) antigens.

Source

Immunogen: Recombinant full-length H1N1 A/New Caledonia/20/99 (MW 72kD) is glycosylated with N-linked sugars and produced using baculovirus vectors in insect cells. The insect cells were infected with A9440.1a, recombinant baculovirus expressing recombinant H1N1 A/New Caledonia/20/99. H1N1 New Caledonia shows 90% similarity to the A/PR/8/34 amino acid sequence.

Product

Formulation: Supplied as a sterile solution in 10mM sodium phosphate, pH 7.2, 150mM sodium chloride.

Purification Method: ? 90% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin: ? 0.1ng/ug (IEU/ug).

Purity: 90% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain.

Concentration: See vial for concentration

ApplicationsOptimal concentration should be evaluated by serial dilutions.ELISA: 1ug/wellWestern Blot: 0.1-1ug/ml

Positive Control: Recombinant full-length H1N1 A/New Caledonia/20/99 (MW 7.5kD) is glycosylated with N-linked sugars and produced using baculovirus vectors in insect cells. The insect cells were infected with A9440.1a, recombinant baculovirus expressing recombinant H1N1 A/New Caledonia/20/99. H1N1 New Caledonia shows 90% similarity to the A/PR/8/34 amino acid sequence.

StorageMay be stored at 4°C for short-term only. For long-term storage, add 0.1% HSA or BSA, store at -20°C. Aliquots are stable for at least 6 months at -20°C.

Product Stability: Reagents are stable for the period shown on the vial label when stored properly

Shipping Conditions: Blue Ice

CautionThis product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio​ accepts no liability for any inaccuracies or omissions in this information.

References1. Wrammert, J., et al. “Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.” J. of Exp. Med. (2011), 208, 181-193.